Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
l-Corydalmine is a tetrahydroprotoberberine alkaloid isolated from the traditional Chinese medicinal plant *Corydalis yanhusuo*. It is currently being developed by Beijing Taizhou Lize Pharmaceutical Technology Co., Ltd. as a potential treatment for methamphetamine addiction. The compound functions primarily as an antagonist of dopamine D1 and D2 receptors, thereby modulating the mesolimbic dopaminergic pathway which is critical for the reinforcing effects of psychostimulants. By inhibiting these receptors, l-corydalmine aims to reduce drug craving and prevent relapse in individuals with substance use disorders. Clinical evaluation has progressed to Phase 1 trials in China, where it is being studied for safety and efficacy in reducing methamphetamine dependence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-corydalmine.